4,5-Dialkylsubstituted 2-imino-1,3-thiazolidine derivatives as potent inducible nitric oxide synthase inhibitors

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 15, 2004, Pages 4101-4116

  Ueda, Shigeo ^a   Terauchi, Hideo ^a   Yano, Akihiro ^a   Matsumoto, Masashi ^a   Kubo, Taeko ^a   Kyoya, Yoko ^a   Suzuki, Kenji ^a   Ido, Motoharu ^a   Kawasaki, Motoji ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

2 Imino 1,3 thiazolidine; Inducible nitric oxide synthase inhibitor; Orally bioavailable

Indexed keywords

ES 1537; NITRIC OXIDE SYNTHASE INHIBITOR; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; NONHUMAN; RAT; STEADY STATE; SUBSTITUTION REACTION;

ANIMALS; CELL LINE; ENZYME INHIBITORS; FEMALE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR; THIAZOLES;

EID: 3042795612     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.05.031     Document Type: Article

References (34)

1. Palmer R.M.J., Ferrige A.G., Moncada S. Nature. 327:1987;524
2. Pfeiffer S., Mayer B., Hemmens B. Angew. Chem., Int. Ed. 38:1999;1714
3. Stuehr D.J., Griffith O.W. Adv. Enzymol. Relat. Areas Mol. Biol. 65:1992;287
4. Rees D.D., Palmer R.M.J., Moncada S. Proc. Natl. Acad. Sci. U.S.A. 86:1989;3375
5. Böhme G.A., Bon C., Lemaire M., Reibaud M., Piot O., Stutzmann J.M., Doble A., Blanchard J.C. Proc. Natl. Acad. Sci. U.S.A. 90:1993;9191
6. Kilbourn R.G., Jubran A., Gross S.S., Griffith O.W., Levi R., Adams J., Lodato R.F. Biochem. Biophys. Res. Commun. 172:1990;1132
7. Grabowski P.S., Wright P.K., Van't Hof R.J., Helfrich M.H., Ohshima H., Ralston S.H. Br. J. Rheumatol. 36:1997;651
8. Miller M.J.S., Sadowska-Krowicka H., Chotinaruemol S., Kakkis J.L., Clark D.A. J. Pharmacol. Exp. Ther. 264:1993;11
9. Wang Y.X., Poon C.I., Pang C.C.Y. J. Pharmacol. Exp. Ther. 265:1993;112
10. Knowles R.G., Palacios N., Palmer R.M.J., Moncada S. Proc. Natl. Acad. Sci. U.S.A. 86:1989;5159
11. Avontuur J.A.M., Boomsma F., Meiracker A.H., Jong F.H., Bruining H.A. Circulation. 99:1999;271
12. Rees D.D., Palmer R.M.J., Schulz R., Hodson H.F., Moncada S. Br. J. Pharmacol. 101:1990;746
13. Narayanan K., Spack L., McMillan K., Kilbourn R.G., Hayward M.A., Masters B.S.S., Griffith O.W. J. Biol. Chem. 270:1995;11103
14. Moore P.K., Wallace P., Gaffen Z., Hart S.L., Babbedge R.C. Br. J. Pharmacol. 110:1993;219
15. Shearer B.G., Lee S., Oplinger J.A., Frick L.W., Garvey E.P., Furfine E.S. J. Med. Chem. 40:1997;1901
16. Nakane M., Klinghofer V., Kuk J., Donnelly J., Budzik G., Pollock J., Basha F., Carter G. Mol. Pharmacol. 47:1995;831
17. Naka M., Nanbu T., Kobayashi K., Kamanaka Y., Komeno M., Yanase R., Fukutomi T., Fujimura S., Seo H.G., Fujiwara N., Ohuchida S., Suzuki K., Kondo K., Taniguchi N. Biochem. Biophys. Res. Commun. 270:2000;663
18. Hagmann W.K., Galdwell C.G., Chen P., Durette P.L., Esser C.K., Lanza T.J., Kopka I.E., Guthikonda R., Shah S.K., MacCoss M., Chabin R.M., Fletcher D., Grant S.K., Green B.G., Humes J.L., Kelly T.M., Luell S., Meurer R., Moore V., Pacholok S.G., Pavia T., Williams H.R., Wong K.K. Bioorg. Med. Chem. Lett. 10:2000;1975
19. Matsuda H., Morikawa T., Ando S., Toguchida I., Yoshikawa M. Bioorg. Med. Chem. 11:2003;1995
20. Matsuda H., Murakami T., Kageura T., Ninomiya K., Toguchida I., Nishida N., Yoshikawa M. Bioorg. Med. Chem. Lett. 8:1998;2191
21. Matsuda H., Morikawa M., Sakamoto Y., Toguchida I., Yoshikawa M. Bioorg. Med. Chem. 10:2002;2527
22. Ueda S., Terauchi H., Yano A., Ido M., Matsumoto M., Kawasaki M. Bioorg. Med. Chem. Lett. 14:2004;313
23. Ueda S., Terauchi H., Kawasaki M., Yano A., Ido M. Chem. Pharm. Bull. 52:2004;634
24. Reetz M.T., Drewes M.W., Schmitz A. Angew. Chem., Int. Ed. 26:1987;1141
25. Andrés J.M., Barrio R., Martínez M.A., Pedrosa R., Pérez-Encabo A. J. Org. Chem. 61:1996;4210
26. Misko T.P., Moore W.M., Kasten T.P., Nickols G.A., Corbette J.A., Tilton R.G., McDaniel M.L., Williamson J.R., Currie M.G. Eur. J. Pharmacol. 233:1993;119
27. Bredt D.S., Snyder S.H. Proc. Natl. Acad. Sci. U.S.A. 87:1990;682
28. X-ray crystal structure of murin iNOS oxygenase domain was reported: Crane B.R., Arvai A.S., Gachhui R., Wu C., Ghosh D.K., Getzoff E.D., Stuehr D.J., Tainer J.A. Science. 278:1997;425
29. Narayanan K., Griffith O.W. J. Med. Chem. 37:1994;885
30. Unpublished results: The selectivity of (4R, 5R)-14a for iNOS couldn't be explained by comparing docking study with our results. The pattern of inhibition of this compound was competitive (Lineweaver-Burk double-reciprocal plot analysis)
31. Szabó C., Southan G.J., Thiemermann C. Proc. Natl. Acad. Sci. U.S.A. 91:1994;12472
32. Full information on the crystal structure can be ordered from Cambridge Crystallographic Data Centre (CCDC), deposition number CCDC 237054
33. Rarey M., Kramer B., Lengauer T., Klebe G. J. Mol. Biol. 261:1996;470
34. Dauber-Osguthorpe P., Roberts V.A., Osguthorpe D.J., Wollf J., Genest M., Hagler A.T. Proteins Struct. Funct. Genet. 4:1988;31